The Patent Finder

Nucleic Acids and Methods of Treatment for Cystic Fibrosis

Arcturus Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 63/019,170, filed May 1, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,788,828Nucleic Acids and Methods of Treatment for Cystic Fibrosis
In force
 · High confidence
Arcturus Therapeutics, Inc.In force
High confidence
US 12,070,509Nucleic Acids and Methods of Treatment for Cystic Fibrosis
In force
 · High confidence
Arcturus Therapeutics, Inc.In force
High confidence
Application 19/688,383Nucleic Acids and Methods of Treatment for Cystic Fibrosis
Pending
Not granted
Arcturus Therapeutics, Inc.PendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Arcturus Therapeutics, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited